• Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

Dbv Technologies S.A.

Headquarters: Montrouge, France
Website: http://www.dbv-technologies.c...
Year Founded: 2002
Status: Public
Industry Sector: HealthTechnology
CEO: Daniel Tassé
Number Of Employees: 109
Enterprise Value: $46,192,022
PE Ratio: -1.67
Exchange/Ticker 1: Euronext Paris:DBV
Exchange/Ticker 2: NASDAQ:DBVT
Latest Market Cap: $275,062,075

BioCentury | Oct 17, 2023
Management Tracks

Allogene named Geoffrey Parker as CFO

Plus: Summit hires Manmeet Soni as COO, and updates from SwanBio, DBV, Lyra and EyePoint
Read More
BioCentury | Dec 23, 2022
Regulation

Dec. 23 Quick Takes: Lunsumio first bispecific for follicular lymphoma

Plus: FDA rebuffs Ipsen’s palovarotene; Amgen, LegoChem in ADC deal; spending bill to Biden; and updates from UCB, Intercept, Galapagos, Ryvu and more   
Read More
BioCentury | Sep 23, 2022
Regulation

Sept. 22 Quick Takes: FDA panel backs Ferring’s microbiota therapy

Plus: expanded label for Lilly and updates from DBV, Albireo, Inventiva and more
Read More
BioCentury | Jul 8, 2022
Finance

Looking for light at the end of biotech’s bear tunnel

3Q22 Financial Markets Preview: As pain grinds on, signals that biotech may be on road to recovery
Read More
BioCentury | Jun 10, 2022
Finance

June 9 Quick Takes: Venture rounds for Tessa, Degron, Ancora, Charm and Relation

Plus Arnay partners with Alloy and updates from DBV and more
Read More
BioCentury | Jun 8, 2022
Politics, Policy & Law

June 7 Quick Takes: Biotech bounce as FTC to scrutinize effect of PBMs on drug prices

Plus DBV meets in peanut-allergic toddlers and updates from Immatics, Edits, Acelyrin and more
Read More
BioCentury | Dec 21, 2021
Product Development

Dec. 21 Quick Takes: CStone’s PD-L1 is China’s newest approved checkpoint inhibitor

Plus: updates from Karyopharm, Ambys, Lilly, Alexion, Gilead, Exuma, DBV, Armgo, Novartis, Intra-Cellular and A-Alpha Bio and Kymera
Read More
BioCentury | Oct 28, 2021
Deals

Oct. 27 Quick Takes: Advancing ‘atlas’ of immunology, Immunai raises $215M

Plus Teva and Modag partner, Fosun, Novavax and DBV
Read More
BioCentury | Aug 24, 2021
Management Tracks

Brun leaves the board at Merck

Plus: Aristea, GT, Connect, Xenon and more
Read More
BioCentury | May 17, 2021
Emerging Company Profile

Allero: treating food-related immune diseases through an oral patch

Emerging Company Profile: Allero is taking an oromucosal path to immune tolerance for food-related immune diseases
Read More
Items per page:
1 - 10 of 88
Help Center
Username
Request Training
Submit Data Correction
Ask a Question
Elevio by Dixa